Lupus, 2020-04, Vol.29 (4), p.426-430
2020
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Alopecia areata in patients with systemic lupus erythematosus treated with belimumab: a plausible association
- Ist Teil von
- Lupus, 2020-04, Vol.29 (4), p.426-430
- Ort / Verlag
- London, England: SAGE Publications
- Erscheinungsjahr
- 2020
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Belimumab, an anti-B-lymphocyte stimulator monoclonal antibody, was recently approved for the treatment of systemic lupus erythematosus. Alopecia areata is characterized by an acute immune-mediated hair loss. Herein, we report on three adult systemic lupus erythematosus patients who developed alopecia areata in association with belimumab treatment. Alopecia areata was resolved in all three patients and belimumab was discontinued in two of them. Thus, in the current report, we explore the plausible link between alopecia areata and belimumab.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0961-2033eISSN: 1477-0962DOI: 10.1177/0961203319899985Titel-ID: cdi_proquest_journals_2390503673
- Format
- –
- Schlagworte
- Adrenal Cortex Hormones - administration & dosage, Adrenal Cortex Hormones - therapeutic use, Adult, Alopecia, Alopecia Areata - chemically induced, Alopecia Areata - drug therapy, Alopecia Areata - pathology, Antibodies, Monoclonal, Humanized - adverse effects, Antibodies, Monoclonal, Humanized - therapeutic use, Antiphospholipid Syndrome - diagnosis, Antiphospholipid Syndrome - drug therapy, Baldness, Female, Humans, Immunosuppressive agents, Immunosuppressive Agents - adverse effects, Immunosuppressive Agents - therapeutic use, Injections, Intralesional, Lupus, Lupus Erythematosus, Systemic - diagnosis, Lupus Erythematosus, Systemic - drug therapy, Lymphocytes B, Male, Monoclonal antibodies, Systemic lupus erythematosus, Treatment Outcome, Withholding Treatment